All Stories

  1. Efficacy of the combination of amphotericin B and echinocandins against Candida auris in vitro and in the Caenorhabditis elegans host model
  2. In Vitro and In Vivo Activity of Citral in Combination with Amphotericin B, Anidulafungin and Fluconazole against Candida auris Isolates
  3. PK / PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris
  4. Assessing pH‐dependent activities of virulence factors secreted by Candida albicans
  5. Antimicrobial Peptides with Anti-Candida Activity
  6. Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?
  7. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
  8. In vitro and in vivo anti-Candida activity of citral in combination with fluconazole
  9. Candidiasis by Candida glabrata, Candida nivariensis and Candida bracarensis in Galleria mellonella: Virulence and Therapeutic Responses to Echinocandins
  10. In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against Candida auris
  11. In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris
  12. Erratum for Miranda-Cadena et al., “Development and Characterization of Monoolein-Based Liposomes of Carvacrol, Cinnamaldehyde, Citral, or Thymol with Anti- Candida Activities”
  13. In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris
  14. Development and Characterization of Monoolein-Based Liposomes of Carvacrol, Cinnamaldehyde, Citral, or Thymol with Anti- Candida Activities
  15. Candida parapsilosis Colony Morphotype Forecasts Biofilm Formation of Clinical Isolates
  16. Virulence of Candida auris from different clinical origins in Caenorhabditis elegans and Galleria mellonella host models
  17. Candida duobushaemulonii: An Old But Unreported Pathogen
  18. Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis , and Candida bracarensis Virulence and Antifungal Efficacy
  19. Synthesis, Physical, Mechanical and Antibacterial Properties of Nanocomposites Based on Poly(vinyl alcohol)/Graphene Oxide–Silver Nanoparticles
  20. Utility of two PCR‐RFLP‐based techniques for identification of Candida parapsilosis complex blood isolates
  21. Graphene Oxide–Silver Nanoparticle Nanohybrids: Synthesis, Characterization, and Antimicrobial Properties
  22. Disinfectant Activity of A Portable Ultraviolet C Equipment
  23. Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: A systematic review
  24. One-step eco-friendly synthesized silver-graphene oxide/poly(vinyl alcohol) antibacterial nanocomposites
  25. Effect of biomaterials hydrophobicity and roughness on biofilm development
  26. Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity
  27. Therapeutic tools for oral candidiasis: Current and new antifungal drugs
  28. Antifungal Activity of the Human Uterine Cervical Stem Cells Conditioned Medium (hUCESC-CM) Against Candida albicans and Other Medically Relevant Species of Candida
  29. Epidemiología de las micosis invasoras: un paisaje en continuo cambio
  30. Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis
  31. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods
  32. Design and validation of a multiplex PCR protocol for microsatellite typing of Candida parapsilosis sensu stricto isolates
  33. The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris
  34. Oral Candida colonization in patients with chronic periodontitis. Is there any relationship?
  35. Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis
  36. Declaración a favor de la creación de la Asociación Iberoamericana de Micología Médica
  37. Editorial: EHUDW01, First EHU-DELFIN Program Workshop, Bilbao, Jul, 201
  38. Comparative Study of Invasive Candidiasis in Mexico and Spain
  39. Phytochemical composition, anti-biofilm and anti-quorum sensing potential of fruit, stem and leaves of Salvadora persica L. methanolic extracts
  40. EPICO 4.0. ‘Total quality’ in the management of invasive candidiasis in critically ill patients by analysing the integrated process
  41. Usefulness of the Non-conventional Caenorhabditis elegans Model to Assess Candida Virulence
  42. Vancomycin heteroresistant community associated methicillin-resistant Staphylococcus aureus ST72-SCCmecIVa strain colonizing the nostrils of a five-year-old Spanish girl
  43. Vancomycin heteroresistant community associated methicillin-resistant Staphylococcus aureus ST72-SCCmecIVa strain colonizing the nostrils of a five-year-old Spanish girl
  44. In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis
  45. Detection and characterization of surface microbial contamination in emergency ambulances
  46. Erratum to: “EPICO 3.0. Management of non-neutropenic patients in medical wards” [Rev Iberoam Micol. 33 (4) (2016) 216–223]
  47. Impact of a multifaceted educational intervention including serious games to improve the management of invasive candidiasis in critically ill patients
  48. Twitter as a Tool for Teaching and Communicating Microbiology: The #microMOOCSEM Initiative †
  49. Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades
  50. EPICO 3.0. Management of non-neutropenic patients in medical wards
  51. Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
  52. Enfermedad fúngica invasiva por Candida y otros hongos levaduriformes
  53. Aspectos actuales de las enfermedades invasoras causadas por Candida y otros hongos levaduriformes
  54. In vitro pharmacodynamic modelling of anidulafungin against Candida spp.
  55. Caries andCandidacolonisation in adult patients in Basque Country (Spain)
  56. Risk Groups for Acquiring Fungal Infections
  57. Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method
  58. Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis
  59. Comparison of the in vitro activity of echinocandins against Candida albicans , Candida dubliniensis , and Candida africana by time–kill curves
  60. In VitroFungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies
  61. Enfermedad fúngica invasiva por hongos filamentosos
  62. Aspectos actuales de las enfermedades invasivas por hongos filamentosos
  63. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations
  64. Candidaantigens and immune responses: implications for a vaccine
  65. Epidemiology of candidaemia and invasive candidiasis. A changing face
  66. State of the Art in the Laboratory Methods for the Diagnosis of Invasive Fungal Diseases
  67. List of Contributors
  68. Presencia de Candida en la estomatitis aftosa recidivante
  69. Épico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients
  70. Proyecto Épico: formulación de unas recomendaciones educativas con metodología DELPHI para pacientes adultos críticos no neutropénicos y con candidiasis invasiva
  71. Épico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients
  72. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis
  73. Enfermedad fúngica invasora: ¿Diagnóstico micológico convencional o molecular?
  74. Accurate Identification of Candida parapsilosis (Sensu Lato) by Use of Mitochondrial DNA and Real-Time PCR
  75. Validation of the PCR–dHPLC method for rapid identification of Candida glabrata phylogenetically related species in different biological matrices
  76. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey
  77. Periodontopathogen and Epstein-Barr Virus Contamination Affects Transplanted Bone Volume in Sinus Augmentation
  78. In vitro activities of natural products against oral Candida isolates from denture wearers
  79. Variation in biofilm formation among blood and oral isolates of Candida albicans and Candida dubliniensis
  80. Prospective Multicenter Study of the Epidemiology, Molecular Identification, and Antifungal Susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Isolated from Patients with Candidemia
  81. Anidulafungin in Treatment of Experimental Invasive Infection by Candida parapsilosis:In VitroActivity, (1→3)-β-d-Glucan and Mannan Serum Levels, Histopathological Findings, andIn VivoEfficacy
  82. In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis
  83. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital
  84. Enfermedades fúngicas invasoras en receptores de trasplante de órgano sólido
  85. Candidiasis, aspergilosis y otras micosis invasoras en receptores de trasplantes de órgano sólido
  86. Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011
  87. Fungicidal Monoclonal Antibody C7 Interferes with Iron Acquisition in Candida albicans
  88. Saccharomyces cerevisiae Vaginitis: Microbiology and In Vitro Antifungal Susceptibility
  89. Clinical factors associated with a Candida albicansGerm Tube Antibody positive test in Intensive Care Unit patients
  90. Evidencias científicas que respaldan el uso de micafungina en el tratamiento de la candidiasis invasora
  91. Posaconazole susceptibility of clinical yeast isolates determined by an agar diffusion and microdilution method
  92. In memoriam a José Pontón
  93. Recomendaciones sobre el diagnóstico de la enfermedad fúngica invasora de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2010
  94. Evaluation of the VITEK 2 system to test the susceptibility ofCandidaspp.,Trichosporon asahiiandCryptococcus neoformansto amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method
  95. In vitroactivity of voriconazole against Mexican oral yeast isolates
  96. Candidemias y candidiasis invasivas nosocomiales
  97. Phospholipase and proteinase activities of Candida isolates from denture wearers
  98. Paradoxical Growth of Candida dubliniensis Does Not Preclude In Vivo Response to Echinocandin Therapy
  99. Kinetic Patterns of Candida albicans Germ Tube Antibody in Critically Ill Patients: Influence on Mortality
  100. Evaluation of CHROM-Pal medium for the isolation and direct identification of Candida dubliniensis in primary cultures from the oral cavity
  101. La Revista Iberoamericana de Micología se debe adaptar a los tiempos actuales
  102. Confundiendo al confuso: reflexiones sobre el factor de impacto, el índice h(irsch), el valor Q y otros cofactores que influyen en la felicidad del investigador
  103. Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients
  104. Evaluation of two commercialized systems for the rapid identification of medically important yeasts
  105. Transient fungaemia due to Candida, pelliculosa in a patient with AIDS
  106. Evaluation of the Albicans IDR plate method for the rapid identification of Candida albicans
  107. Actividad antifúngica in vitro de la micafungina
  108. Actividad de la micafungina contra las biopelículas de Candida
  109. Micafungina, una nueva candina para el tratamiento de las micosis invasoras
  110. Isolation of Candida dubliniensis in denture stomatitis
  111. Enteric Fever-Like Syndrome Caused by Raoultella ornithinolytica (Klebsiella ornithinolytica)
  112. In VitroAntifungal Activity of Sertaconazole Nitrate Against Recent Isolates of Onychomycosis Causative Agents
  113. Anidulafungina en la infección fúngica invasora: perspectivas actuales
  114. Actividad antifúngica in vitro de la anidulafungina
  115. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis
  116. Latest developments in fungal lung infection in solid organ transplantation (SOT)
  117. En la primera vuelta de la segunda escalera me volví y contemplé: 25 años de Revista Iberoamericana de Micología
  118. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre
  119. Evaluación comparativa de ATB Fungus 2 y Sensititre YeastOne en el estudio de la sensibilidad in vitro de Candida a los antifúngicos
  120. In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp.
  121. Isolation ofCandida africana, probable atypical strains ofCandida albicans, from a patient with vaginitis
  122. Activity of Caspofungin and Voriconazole against Clinical Isolates of Candida and Other Medically Important Yeasts by the CLSI M-44A Disk Diffusion Method with Neo-Sensitabs Tablets
  123. Actividad in vitro de la anfotericina B y la anidulafungina sobre biopelículas de Candida albicans y Candida tropicalis
  124. Identificación rápida de Candida dubliniensis mediante la prueba Bichro-Dubli®
  125. In vitro activity of micafungin combined with itraconazole against Candida spp.
  126. Presente y futuro de voriconazol en el tratamiento de las micosis invasoras: el inseparable binomio diagnóstico-tratamiento
  127. Actividad antifúngica in vitro de voriconazol: Nuevos datos después de los primeros años de experiencia clínica
  128. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis
  129. Comparación de un método de amplificación aleatoria del ADN polimorfo (RAPD) y el sistema ATB ID32C para la identificación de aislamientos clínicos de Candida
  130. In vitro interaction of micafungin and fluconazole against Candida
  131. Comparison of Tablet and Disk Diffusion Methods for Fluconazole and VoriconazoleIn VitroActivity Testing Against Clinical Yeast Isolates
  132. La valiosa incorporación del nuevo Director ejecutivo, Josep Guarro i Artigas
  133. Biofilm development by clinical isolates ofMalassezia pachydermatis
  134. Update on invasive fungal infections: the last two years
  135. New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi
  136. Utilidad de la detección de (1→3)-ß-D-glucano y anticuerpos anti-micelio de Candida albicans para el diagnóstico y seguimiento terapéutico de la candidiasis invasora en pacientes neutropénicos adultos
  137. Aislamiento de Issatchenkia occidentalis en el esófago de un paciente con leucemia
  138. In Vitro Activities of Voriconazole and Five Licensed Antifungal Agents Against Candida dubliniensis: Comparison of CLSI M27-A2, Sensititre YeastOne, Disk Diffusion, and Etest Methods
  139. Evaluation of the New Chromogenic Medium Candida ID 2 for Isolation and Identification of Candida albicans and Other Medically Important Candida Species
  140. In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast OneTM
  141. Evaluation of Bichro-Dubli Fumouze® to distinguish Candida dubliniensis from Candida albicans
  142. Anticuerpos anti-micelio de Candida albicans en dos pacientes de cuidados intensivos con candidiasis invasora
  143. Mecanismos de resistencia a la terapéutica antifúngica
  144. Usefulness of Candida ID2 agar for the presumptive identification ofCandida dubliniensis
  145. Introduction to the special issue of the Revista Iberoamericana de Micología devoted to Fungal Genomes
  146. Supplementation of CHROMagar Candida Medium with Pal's Medium for Rapid Identification of Candida dubliniensis
  147. Oral Candida Isolates Colonizing or Infecting Human Immunodeficiency Virus-Infected and Healthy Persons in Mexico
  148. Sertaconazole: updated review of a topical antifungal agent
  149. Actividad antifúngica in vitro de voriconazol contra dermatofitos y aislamientos superficiales de Scopulariopsis brevicaulis
  150. Prevalencia, microbiología y patrones de sensibilidad a los antifúngicos de los aislamientos orales de Candida que colonizaban o infectaban a pacientes mexicanos con infección por VIH o sida y a personas sanas
  151. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections
  152. Current Developments in Anti-Fungal Agents
  153. Evaluation of API ID 32C® and VITEK-2® to identify Candida dubliniensis
  154. Antifungal Activity of Amphotericin B and Itraconazole against Filamentous Fungi: Comparison of the Sensititre Yeast OneŴ and NCCLS M38-A Reference Methods
  155. Evaluación de una nueva técnica comercializada (Candida albicans IFA IgG) para el diagnóstico de la candidiasis invasiva
  156. In vitro Antifungal Activity of Sertaconazole Compared with Nine Other Drugs against 250 Clinical Isolates of Dermatophytes and Scopulariopsis brevicaulis
  157. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans
  158. Performance of BacticardTM Candida compared with the germ tube test for the presumptive identification of Candida albicans
  159. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species
  160. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method
  161. Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates
  162. Candida dubliniensis, a new fungal pathogen
  163. Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P
  164. Comparison of the Sensititre YeastOne Colorimetric Microdilution Panel and the NCCLS Broth Microdilution Method for Antifungal Susceptibility Testing against Candida Species
  165. Serological Differentiation of Experimentally Induced Candida dubliniensis and Candida albicans Infections
  166. Comparative evaluation of three commercial software packages for analysis of DNA polymorphism patterns
  167. S2.5 Nuevas perspectivas en la terapia antifúngica
  168. Sertaconazole:In-VitroAntifungal Activity Against Vaginal and Other Superficial Yeast Isolates
  169. In Vitro Activity of a New Liposomal Nystatin Formulation Against Opportunistic Fungal Pathogens
  170. Effect of salivary secretory IgA on the adhesion of Candida albicans to polystyrene
  171. Influence of Environmental pH on the Reactivity of Candida albicans with Salivary IgA
  172. Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex, Amphotericin B and Fluconazole
  173. In vitro Susceptibility of Candida dubliniensis to Current and New Antifungal Agents
  174. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients
  175. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole
  176. A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.
  177. Comparison of morphotypic and genotypic methods for strain delineation inCandida
  178. Reactivity of Candida albicans Germ Tubes with Salivary Secretory IgA
  179. Utility of albicans ID plate for rapid identification of Candida albicans in clinical samples
  180. Effect of monoclonal antibodies directed against Candida albicans cell wall antigens on the adhesion of the fungus to polystyrene
  181. Cytological changes in oral mucosa in denture stomatitis
  182. Candida biotypes in patients with oral leukoplakia and lichen planus
  183. Evaluation of a commercial medium for identification ofCandida species
  184. A new method of antibiotyping yeasts for subspecies discrimination and distribution in human clinical specimens
  185. Variability in expression of antigens responsible for serotype specificity in Candida albicans
  186. Biotype Diversity of Candida parapsilosis and Its Relationship to the Clinical Source and Experimental Pathogenicity
  187. Use of DNA fingerprinting and biotyping methods to study a Candida albicans outbreak in a neonatal intensive care unit
  188. Fatal Candida famata Peritonitis in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis Who Was Treated with Fluconazole
  189. Prevalence of Candida parapsilosis in the Oral Cavities of Infants in Spain
  190. Multicenter Evaluation of ATB Fungus: A Standardized Micromethod for Yeast Susceptibility Testing
  191. Detection of Anti-CandidaalbcansIgE Antibodies in Vaginal Washes from Patients with Acute Vulvovaginal Candidiasis
  192. Fatal Disseminated Infection by Scedosporium inflatum after Bone Marrow Transplantation
  193. Identification of antigens reacting with anti-Candida albicans germ tube antibodies
  194. Vulvovaginal candidiasis refractory to treatment with fluconazole
  195. Candidal infection of bone: Assessment of serologic tests in diagnosis and management
  196. In vitro susceptibility ofAeromonas caviae, Aeromonas hydrophila andAeromonas sobria to fifteen antibacterial agents
  197. Value of detection of antibodies toCandida albicans germ tube in the diagnosis of systemic candidosis
  198. Determination of monosaccharides by high-performance liquid chromatography in systemic candidosis
  199. Vulvovaginal Candidiasis: pathogenesis and diagnosis
  200. Antibodies against Trichosporon beigelii in vaginal washings from asymptomatic women
  201. Isolation of dysgonic strains ofMicrosporum canisin Bilbao (Spain)
  202. Detection of antibodies toCandida albicans germ tube in the diagnosis of systemic candidiasis
  203. Cellular and humoral immune responses to Candida albicans in subcutaneously infected mice
  204. Typing Fungal Isolates: Molecular Methods and Computerized Analysis
  205. Trichosporon, Magnusiomyces, and Geotrichum